PMC:7696151 / 76913-77181
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2245 | 3-7 | Species | denotes | mice | Tax:10090 |
| 2254 | 48-51 | Chemical | denotes | HCQ | MESH:D006886 |
| 2255 | 165-168 | Chemical | denotes | HCQ | MESH:D006886 |
| 2256 | 198-209 | Chemical | denotes | vemurafenib | MESH:D000077484 |
| 2272 | 37-46 | Disease | denotes | carcinoma | MESH:D009369 |
| 2273 | 126-131 | Disease | denotes | tumor | MESH:D009369 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T159 | 37-46 | Phenotype | denotes | carcinoma | http://purl.obolibrary.org/obo/HP_0030731 |
| T160 | 126-131 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T494 | 0-268 | Sentence | denotes | In mice with thyroid gland xenograft carcinoma, HCQ (150 mg/kg/day p.o. for two weeks) did not provide significant results on tumor growth, while the combination of HCQ with the chemotherapic agent vemurafenib potentiated the anticancer properties of both drugs [147]. |